Olr1733 inhibitors represent a distinct chemical class of compounds that specifically target the Olr1733 protein, which belongs to the olfactory receptor family. These receptors are part of the G protein-coupled receptor (GPCR) superfamily, which play crucial roles in signal transduction across cell membranes. Olr1733, in particular, is associated with the perception of odor molecules, functioning as a sensor that detects specific ligands in the environment. The inhibition of Olr1733 is achieved by compounds that bind to the active or allosteric sites of the receptor, thereby preventing the normal activation of the receptor by its natural ligands. These inhibitors are characterized by their structural diversity, which includes both small organic molecules and larger, more complex entities, reflecting the versatility required to achieve specificity and potency in their inhibitory action.
The study of Olr1733 inhibitors involves a detailed understanding of the receptor's structure, including its transmembrane domains, ligand-binding sites, and the conformational changes it undergoes upon activation. Structural analyses often utilize techniques such as X-ray crystallography or cryo-electron microscopy to elucidate the binding interactions at an atomic level. Computational methods, including molecular docking and dynamics simulations, further aid in predicting the binding affinities and inhibitory mechanisms of these compounds. Additionally, the development of Olr1733 inhibitors is informed by structure-activity relationship (SAR) studies, which correlate specific chemical modifications with changes in inhibitory potency. These studies are essential for optimizing the molecular properties of the inhibitors, such as selectivity, binding affinity, and metabolic stability, thereby advancing the understanding of how chemical inhibition can modulate olfactory receptor functions at the molecular level.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affecting protein degradation pathways relevant to Olr1733. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Multi-kinase inhibitor, could affect angiogenesis and cell proliferation pathways impacting Olr1733. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Src family kinase inhibitor, potentially altering cell proliferation and survival pathways affecting Olr1733. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
EGFR tyrosine kinase inhibitor, could disrupt signaling pathways that regulate Olr1733 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
BCR-ABL tyrosine kinase inhibitor, might influence signaling pathways regulating Olr1733. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual EGFR and HER2 inhibitor, potentially modulating signaling pathways relevant to Olr1733's function. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL kinase inhibitor, could impact cell proliferation and survival pathways influencing Olr1733. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
CDK4/6 inhibitor, might modulate cell cycle regulation pathways impacting Olr1733. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Inhibits multiple tyrosine kinases, potentially affecting pathways influencing Olr1733, like angiogenesis or cell proliferation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Multi-targeted receptor tyrosine kinase inhibitor, could disrupt several signaling pathways involving Olr1733. | ||||||